Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche span> par promoteur : Orion Corporation Orion Pharma
Homme Max 99 ans
Orion Corporation Orion Pharma
MAJ Il y a 5 ans
SAFETY AND TOLERABILITY OF ODM-201 IN PATIENTS WITH PROSTATE CANCER: EXTENSION STUDY TO STUDY 3104001
The primary objective of this extension study is to gain more information about the long-term safety and tolerability of ODM-201.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Orion Corporation Orion Pharma, FI-02200 Espoo, Finland
MAJ Il y a 5 ans
Efficacy and safety of Stalevo in subjects with early wearing-off identified using a screening tool WOQ-9; An open, non-randomised, multinational, multi-centre 6-week direct switch study in levodopa-treated Parkinson's disease patients
to provide efficacy data of the direct switch from levodopa/carbidopa or levodopa/benserazide to levodopa/carbidopa/entacapone (Stalevo®) by clinical global impression of change (CGI-C) as judged by t...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Orion Corporation Orion Pharma
MAJ Il y a 5 ans
Effects of single doses of Stalevo 200 and levodopa/carbidopa 200/50 mg on striatal 11C-raclopride binding potential in Parkinson’s disease patients with wearing-off symptoms. An open, randomised, active-controlled, two-period crossover study
To compare the effect of Stalevo 200 and Sinemet on the change of striatal (butaminal and caudate) 11C-raclopride binding potential (BP) from baseline in PD patients with wearing-off symptoms.
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Orion Corporation Orion Pharma
MAJ Il y a 5 ans
First in human study with ODM-207 in patients with selected advanced cancers to assess its safety and how the body affects it
Part 1: To evaluate the safety and tolerability, define the maximum tolerated dose (MTD) and dose limiting toxicities (DLTs) if possible, and define the recommended doses and dosing schedules of ODM...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Homme Max 99 ans
Orion Corporation Orion Pharma
MAJ Il y a 5 ans
A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF ODM-201 IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER Studio multinazionale, randomizzato, in doppio cieco, controllato con placebo, di Fase III, per valutare l’efficacia e la sicurezza di ODM-201 in pazienti di sesso maschile con cancro della prostata resistente alla castrazione non metastatico ad alto rischio
The primary objective of this study is to demonstrate the superiority of ODM-201 vs. placebo in metastasis free survival (MFS) in patients with high-risk nmCRPC
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Précédent
1
2